Innovent Biologics and Pfizer Strike $10.5 Billion Cancer Drug Deal

Author: Noah Taylor…

Innovent Biologics and Pfizer Strike $10.5 Billion Cancer Drug Deal

Chinese biopharmaceutical firm Innovent Biologics and U.S. pharma giant Pfizer have signed a global licensing and collaboration deal worth up to $10.5 billion to research and develop 12 early-stage cancer medicines. The companies announced the deal on Friday.

Deal Details

Under the agreement, Innovent Biologics will license global rights to certain cancer drugs to Pfizer. Pfizer will pay an upfront payment, development and commercial milestone payments, and royalties for the development and commercialization of these drugs. The total value could reach $10.5 billion.

Industry Impact

This deal is part of a trend where Chinese biotech firms partner with global pharma giants. Innovent Biologics' shares trade on the Hong Kong Stock Exchange (ticker: 1801), while Pfizer is listed on the New York Stock Exchange (ticker: PFE).

Impacted Symbols

Symbols affected by this headline and their sentiment signals

1801Positive

Taisei Corporation

Innovent Biologics secured a major global deal, providing significant revenue and growth potential.

Impact score85%

PFEPositive

Pfizer, Inc.

Pfizer expands its cancer drug portfolio with long-term growth opportunity, but the high deal value may have short-term cost impact.

Impact score70%

The news, analyses, and comments on this platform do not constitute investment advice. When making investment decisions, you should conduct your own research and consult with a qualified financial advisor if necessary. FiNews cannot be held responsible for any losses that may arise from the use of this information.

More Headlines